C
Counsyl
DNA screening and genetic counseling for diseases that can impact men, women & their children. Counsyl is the US leader in ECS
About Counsyl
Myriad Women's Health, formerly known as Counsyl, specializes in genetic testing services aimed at reproductive health. The company operates in the healthcare sector, focusing on providing genetic screening and counseling services to individuals planning a pregnancy or concerned about their reproductive health. Myriad Women's Health serves a diverse range of clients, including patients, healthcare providers, and telehealth platforms. The business model revolves around offering genetic tests that can be ordered online or through healthcare providers, followed by detailed counseling sessions to interpret the results. Revenue is generated through the sale of these genetic tests and associated counseling services. The company leverages telehealth to make genetic testing more accessible, especially in the post-COVID-19 world, where remote healthcare solutions are increasingly in demand.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2007
- Headquarters
- San Francisco, United States
- Employees
- 47
- Open positions
- None listed
- Dealroom signal
- 69.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Accounting, Testing, Risk Management, Analytics, Biotechnology, Oncology, DNA, Invoicing, Genetics and genomics
- Business model
- Manufacturing, Marketplace & ecommerce
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2018 | $375M | — | Myriad Genetics | — |
| FundingOther financing | Nov 2017 | $80M | — | Goldman Sachs · Felicis · Pilot Growth Equity · Founders Fund | — |
Growth signals
Latest recorded traffic for Counsyl is 81K monthly website visits, down 15.6% over the last three months. Counsyl's team declined 27.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
Pilot Growth Equity
Founders Fund
Felicis
Goldman Sachs- RPRosemont Seneca Partners
Other known investors1 additional known investor
Myriad Genetics
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Counsyl on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Counsyl’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.